Dasher Neuroscience Completes Recruitment for YA-101 Phase 2 Trial
Dasher Neuroscience completed patient recruitment for a global Phase 2 trial of YA-101 for multiple system atrophy, the company announced in a press release.
The trial enrolled 90 participants at clinical sites in the United States, Japan, and Taiwan. It is a global, multicenter, double blind, placebo controlled, dose escalation study evaluating safety, tolerability, pharmacokinetics, and efficacy in patients aged 30 and older with multiple system atrophy.
The primary endpoint is the frequency and severity of adverse events. Secondary endpoints include pharmacokinetic measures and clinical efficacy, assessed using the Unified Multiple System Atrophy Rating Scale and the 10 meter walk test.
Dasher said top line clinical data are expected in the first quarter of 2027. YA-101 has FDA Fast Track status and Orphan Drug status in the United States, Japan, and the European Union.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 28 Deep Longevity to Launch Accrua Telehealth Platform in US Sep 28 United Imaging Intelligence Releases Medical Video AI Framework Sep 28 Orca Dental AI Brings CephX Imaging Tools to Planet DDS Cloud 9 Sep 28 AINGENS Warns AI Tool Fragmentation Complicates Medical Affairs Work Sep 28 Blue Cross Analysis Links Hospital AI to $942 Million in Added CostsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
ARPA-H Awards UpDoc Up to $9.2 Million for Clinical AI
AEYE Health Publishes Diabetic Retinopathy Screening Trial Results
Superluminal Medicines Raises $60 Million for Obesity Drug Trial
Axya Raises C$17 Million for AI Procurement Platform
AI in Clinical Trials Market Forecast to Reach USD 7.32 Billion by 2034
Daily AI Brief: the AI news that matters, in your inbox.